Neonatal Fc Receptor Blockers for Myasthenia Gravis: The Concept Is Now Reality
While acetylcholinesterase inhibitors, corticosteroids and thymectomy are generally considered first-line therapies for MG, many patients additionally require proven immunosuppressive therapies (ISTs) such as azathioprine, cyclosporine/tacrolimus or mycophenolate mofetil, or immunomodulatory therapies, including intravenous immune globulin (IVIG) or plasma exchange (PLEX).
The Current Challenge of Immune Globulin Access
Understanding the factors contributing to the current shortage of immune globulin could help to address a crisis that threatens dire consequences for patients.
High Oncotic Pressure Cardiopulmonary Bypass Priming with Human Albumin Improves Outcomes in Pediatric Open-Heart Surgery
Specialists at India’s Sir Ganga Ram Hospital conducted a double-blinded, randomized controlled study to examine the impact of high oncotic pressure priming by the addition of 20 percent human albumin prior to the initiation of CPB
First-Line Intravenous Immune Globulin Monotherapy Evaluated in Idiopathic Inflammatory Myopathy
The investigators concluded first-line IVIG monotherapy led to clinically relevant improvement in nearly one-half of IIM patients, the majority of whom experienced a rapid clinical response.
Predictive Medicine: How DNA Testing Is Influencing Healthcare
Will genetic testing and whole genome sequencing become part of the standard of care in treating patients?
Live Donor Organ Transplant: A Physician’s Perspective
Nancy Ascher, MD, PhD, has devoted her career to organ transplantation and transplant surgery.
Anti-COVID Monoclonal Cocktails
Newly created treatments for high-risk COVID-19 patients have proved highly effective. Unfortunately, challenges with their distribution and administration have limited their use.
Hemophilia Gene Therapy: Cures May Finally Be at Hand
The decades-old dream is to correct the factor deficiency through a single infusion of a hemophilia gene therapy that produces steady high protective levels of FVIII or FIX.
Subcutaneous Immune Globulin May Be a Treatment Option in Stiff Person Syndrome Patients Intolerant to Intravenous Immune Globulin
SCIG may be a reasonable and safe alternative for SPS patients who do not tolerate IVIG, with the caveat that allergic and injection site reactions can be a limiting factor for some patients.
Low Rate of Inhibitor Development in Previously Untreated Hemophilia A Patients Managed with Simoctocog Alfa (Nuwiq)
The investigators concluded PUPs treated with simoctocog alfa had a lower high-titer inhibitor rate than PUPs initially treated with hamster-cell-derived recombinant FVIII products.
